Joe Biehl Named CEO of Healthcare Innovation Catalysts

Healthcare Innovation Catalysts Inc. (HIC) has welcomed a new leader, appointing Joseph (Joe) Biehl as CEO.

Biehl has more than 35 years of healthcare and life science industry experience, as he has led, directed, and managed various life science service organizations for companies in U.S. Food and Drug Administration-regulated industries throughout the United States, Canada, Europe, and Asia. In his role at HIC, Biehl will continue to build HIC’s cross-functional technical expertise and expand its global presence.

“Joe is a proven and trusted leader with a deep understanding of the life sciences service industry on a global scale. We are thrilled to have him lead HIC through its next evolution,” HIC Executive Chairman Michael Singer said. “He brings a wealth of experience to HIC as a leader, strategist, and client satisfaction agent.”

Before arriving at HIC, Biehl held many roles at ProPharma, a large, established global life sciences consultancy with more than 1,000 professionals worldwide providing regulatory, quality, and compliance services to pharmaceutical, biotech, and medical device companies. His roles included senior vice president of Consulting Operations and general manager of the Americas and APAC. Most recently, he was president of Global Key Accounts.

“I am excited to join HIC given its track record of delivering regulatory, clinical, compliance, and quality services to clients worldwide,” Biehl stated. “I look forward to working with the HIC team to continue to build on our strong customer-focused foundation.”

Healthcare Innovation Catalysts Inc. was founded in 2022 to fill a gap in the advisory services available to the global life sciences industry. HIC helps its clients envision and reach daunting goals and overcome appreciable obstacles. The organization includes experts from government, industry, and academia across disciplines, including regulatory affairs, clinical advisory, biostatistics, quality, compliance, and federal partnerships. Among many other things, HIC has brought novel drugs, biotech products, and medical devices through the clinical development and approval processes; audited clinical trials, manufacturing sites, and labs; developed federal partnerships; and resolved significant compliance problems.